oligodendroglioma pathology outlines

Oligodendrogliomas. Oligodendroglioma - Wikipedia CIC normally functions as a reversible repressor by binding to the DNA regulatory elements downstream of growth factor signaling pathways (Ajuria et al., 2011). Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. Nature 529, 110114. Two main alterations affecting the TCF12 protein have been reported in AO: absence of bHLH DNA-binding domain and single amino acid substitutions such as R602M within the bHLH domain. [2]. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. doi: 10.1016/j.celrep.2015.11.029, Warnick, R. E., Prados, M. D., Mack, E. E., Chandler, K. L., Doz, F., Rabbitt, J. E., et al. 1985 Jul 1. doi: 10.1215/15228517-2005-009, PubMed Abstract | CrossRef Full Text | Google Scholar. 112, 801809. 19 (suppl_5):v1-v88. Oligodendroglioma is considered the third most common glioma accounting for 2%-5% of primary brain tumors and 5%-18% of all glial neoplasms 8. Two of 10 central neurocytomas and 2/10 clear cell ependymomas showed focal OLIG2 expression. 0000276833 00000 n Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). (2012) reported the survival benefit of immunotherapy in patients with relapsed AO enrolled in the HGG-IMMUNO-2003 trial. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. doi: 10.1016/j.ccr.2010.12.014, Yip, S., Butterfield, Y. S., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., et al. (WC/jensflorian), Perinuclear MAP2 immunoreactivity in oligodendroglioma. An immunohistochemical and electron microscopic study. Neurol Med Chir (Tokyo). J. Clin. CT imaging of oligodendroglioma - ScienceDirect Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. In addition to the aforementioned pathways, homozygous and the less common hemizygous losses of 9p21 have been reported with high frequencies in gliomas, and up to 55% in AO (Maruno et al., 1996; Perry et al., 1999; Rasheed et al., 2002; Ohgaki and Kleihues, 2009; Michaud et al., 2018). When possible, the sample is removed during surgery to remove the tumor. Pediatric oligodendroglioma is a low-grade glioma that remains relatively rare when compared to adults. On magnetic resonance imaging, he was considered to have disease progression. 0000127092 00000 n 12,142 Images : Last Update : Apr 23, 2023. The machine sends beams to exact points in your brain. Ann Neurol. However, a clear distinction of both grades is not always possible. Science 289:905. Pharm. 0000280922 00000 n Report of thirty-nine cases. The tissue sample goes to a lab for testing. The p16INK4a/CDKN2A tumor suppressor and its relatives. Oncol. Oligodendroglioma: pathology, molecular mechanisms and markers 10, 295307. Your oncologist might recommend a combination of medications - procarbazine, lomustine, and vincristine. Oligodendroglioma is genetically defined as a tumor confirmed to harbor either an IDH1 or IDH2 mutation along with co-deletion of chromosome arms 1p and 19q. K.-Y., Pang, J. C.-S., Chung, N. Y.-F., Li, K. K.-W., Poon, W. S., Chan, D. T.-M., et al. Delays in diagnosis are likely to occur given the nature of pediatric oligodendroglioma. (Dec 2014). Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. doi: 10.1523/JNEUROSCI.0160-09.2009, Fujii, Y., Muragaki, Y., Maruyama, T., Nitta, M., Saito, T., Ikuta, S., et al. Accessed Sept. 26, 2022. Oligodendrogliomas arise in the cerebral hemispheres and have a predilection for the frontal lobes. Few neural tumours have round nuclei - DDx in intraoperative specimen: High mitotic rate (6 or more mitoses/10 HPF of 0.55mm). Oligodendroglioma, Brain Tumor: Causes, Symptoms & Treatments mTOR-dependent cell proliferation in the brain. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. 8th ed. 12, 20132021. This previously diagnosed oligoastrocytoma,, For unequivocal assessment of 1p/19q codeletion in oligodendroglial tumors, detection of whole-arm losses, MeSH -, Appin CL, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, Schniederjan MJ, Hadjipanayis C, Olson JJ, Hunter S, et al. Molecules 24:968. doi: 10.3390/molecules24050968, Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., and Diaz, L. A. Jr. et al. Anaplastic oligodendroglioma. A brain tumor survivor shares his experience with oligodendroglioma and advice for others. 0000277188 00000 n doi: 10.1212/wnl.46.1.203, Michaud, K., de Tayrac, M., DAstous, M., Paquet, C., Gould, P. V., and Saikali, S. (2018). Nature 483, 484488. This content does not have an English version. Megyesi JF, Kachur E, Lee DH, et al. Oligodendroglioma | Radiology Reference Article | Radiopaedia.org [QxMD MEDLINE Link]. 2012 Jun;123(6):853-60. doi: 10.1007/s00401-012-0993-5. 0000225786 00000 n 0000230693 00000 n As part of an ongoing phase 1 trial to treat recurrent malignant gliomas (NCT03152318), investigators hope that the rQNestin34.5v.2 drug will spread to a glioma cell, kill it, and then make a copy of itself and spread again. IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. 0000247714 00000 n [4]. Cerebral oligodendroglioma: prognostic factors and life history. Appl. Recent advances in molecular profiling technology, including comprehensive DNA sequencing CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. In practice, (neuro)pathologists who readily accept the existence of mixed gliomas will more liberally diagnose oligoastrocytomas, while those who are skeptical that this entity exists will designate the vast majority of diffuse gliomas as either astrocytic or oligodendroglial (, Example of how molecular reclassification may affect tumor grade. This means it begins in the brain or spinal cord. Infiltration of immune cells, specifically T cells, were also reduced in these tumors (Amankulor et al., 2017; Kohanbash et al., 2017). 0000349212 00000 n During this type of surgery, you're awakened from a sleep-like state. Front. (2003). 287, 27982809. These alterations have correlated with a shorter event free survival (EFS; 29 vs. 53 months, p < 0.0001) and OS (48 vs. 83 months, p < 0.0001). [QxMD MEDLINE Link]. Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. van den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. Oncol. Oncol. The wildtype (WT) TERT group was associated with good prognosis only in IDH1/IDH2 WT (IDH-WT) grade II/III astrocytomas. Chemotherapy for low grade oligodendrogliomas. 2008 Aug. 15(8):946-9. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas. PNET Survivor Shares Coping Tips 1995. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. A randomized clinical trial is currently in progress to compare the efficacy of PCV or TMZ when combined with RT in 1p19q co-deleted tumors (CODEL: NCT00887146). 1994 Dec. 35(6):1018-34; discussion 1034-5. J. Clin. Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. (1996). (2003). UpToDate The second is diminished intracellular drug transport through the overexpression of ATP-binding cassette transporter proteins such as P-gp (MDR1), MRP1, and MRP5 (Calatozzolo et al., 2012; Alms et al., 2014). While increasing the risk of toxicity, concurrent TMZ is currently being assessed in comparison to adjuvant treatment in astrocytic tumors (van den Bent et al., 2017). Throughout the entire process, educate the patient and family through regular follow-up care and involvement of support groups to cope with physical, emotional, and spiritual stress. A chemotherapy called temozolomide is also being studied in clinical trials. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, WHO CNS Grade 3 (ICD-O: 9451/3). Adv Anat Pathol. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. J. Analysis from the initial study design. Mutant IDH1 has also been shown to inhibit the ALkB family DNA repair enzymes further contributing to erroneous DNA replication (Wang et al., 2015; Rinaldi et al., 2016). This trial aims to determine the maximum tolerated dose of ONC206. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. 0000277266 00000 n 2004 Jul 1. 8, 183188. doi: 10.12786/bn.2022.15.e23. (Feb 2007). Macdonald, D., Cairncross, G., Stewart, D., Forsyth, P., Sawka, C., Wainman, N., et al. Polymorphous low-grade neuroepithelial tumor of the young - PubMed Typically, they have an indolent course, and patients may survive for many years after symptom onset. Schold SC, Burger PC, Minna JD, et al. Kang SG, Kim JH, Nam do H, Park K. Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Want to use this content on your website or other digital platform? 29, 1139911408. A neuropathologist should then review the tumor tissue. 0000222846 00000 n J. Clin. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. 0000245546 00000 n 27:5874. doi: 10.1200/jco.2009.23.6497, Wick, W., Roth, P., Hartmann, C., Hau, P., Nakamura, M., Stockhammer, F., et al. <<950B2C5CEB56DC43B0B6FC5D5B108F3A>]/Prev 655139/XRefStm 2967>> J Clin Oncol. doi: 10.3171/JNS/2008/108/2/0227, Chang, S. M., Kuhn, J. G., Robins, H. I., Schold, S. C. Jr., Spence, A. M., Berger, M. S., et al. Retrospective studies have revealed that the post-operative seizure-free rate is 6780% (Luyken et al., 2003; Zaatreh et al., 2003; Benifla et al., 2006; Chang et al., 2008; Englot et al., 2011). Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome. Few calcifications are present. Another factor that increases probability of survival in low-grade gliomas is a high performance status. Oligodendroglioma - Libre Pathology xref With proper education, the patient and family can develop good insight into the course and prognosis of the tumor. Cancer 91, 417422. Preliminary results are mentioned toward the end of the manuscript. 0000141681 00000 n Eight of 10 central neurocytomas, all clear cell meningiomas and 8/10 clear cell ependymomas were negative for OLIG2. Neuro Oncol. (2017). 131, 803820. MRI: frontal lobe tumor with cystic change, Vote for your favorite image from the PathologyOutlines.com Directory. J. Neurosurg. (Aug 2013). TCF12 is mutated in anaplastic oligodendroglioma. CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. If the tumor can't be removed with surgery, a sample might be collected with a needle. Oligodendroglioma of the fourth ventricle with intracranial and spinal oligodendrogliomatosis: a case report. J. Neurosurg. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Contributed by Jared T. Ahrendsen, M.D., Ph.D. and John DeWitt, M.D., Ph.D. Neuro Oncol. Another phase 2 clinical trial (NCT04623931) is assessing chemotherapy and RT for the treatment of IDH wildtype gliomas or non-histological glioblastomas in approximately 40 patients. Careers. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C. Acta Neuropathol. During radiation therapy, you lie on a table while a machine moves around you. Sahm, F., Koelsche, C., Meyer, J., Pusch, S., Lindenberg, K., Mueller, W., et al. 0000255421 00000 n doi: 10.1200/JCO.2012.43.2229. Consider Glioblastoma with oligo features when tumor is IDH1/2 wildtype and has no LOH 1p/19q and no ATRX loss. 2022 Dec 23;13:587. doi: 10.25259/SNI_792_2022. Ahmad H, Martin D, Patel SH, Donahue J, Lopes B, Purow B, et al. The end result is DNA hypermethylation and thus the blockage of cellular differentiation (Kaminska et al., 2019). Please confirm that you would like to log out of Medscape. Molecular analysis of IDH1/2 hotspots and LOH1p/19q testing is required for diagnosis. 0000276911 00000 n doi: 10.1111/j.1349-7006.2009.01308.x, Ostrom, Q. T., Gittleman, H., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C., et al. (2019) depicted how the mutant IDH1 (R132H) blocks cellular differentiation and contributes to antitumor immunity. Moreover, no mutations were found in ERCC6 exon 2 and only two patients had a chemotherapeutic response, but with unexpected short survival times. 79, 153157. Cancer. There are 11 ongoing clinical trials recruiting patients with AO. Douglas E Ney, MD is a member of the following medical societies: American Academy of Neurology, American Society of Clinical Oncology, Society for Neuro-OncologyDisclosure: Nothing to disclose. doi: 10.1093/neuonc/nox158. 21(13):2525-8. J. Neurosurg. Polymorphous low-grade neuroepithelial tumor of the young: case report Procarbazine, CCNU, vincristine (PCV) chemotherapy for benign oligodendroglioma. Adekunle M Adesina, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Neuropathologists, College of American Pathologists, United States and Canadian Academy of PathologyDisclosure: Nothing to disclose. Neurosurgery. Oligodendrogliomas rarely spread outside of the CNS to other organs. Tork, C. A., and Atkinson, C. (2020). 2014;37:E13. (2003). Neurology 61, 636641. doi: 10.3171/2017.3.JNS162383, Fulton, D., Urtasun, R., and Forsyth, P. (1996). (Jan 2015). Adult central nervous system tumors treatment (PDQ) Patient version. All in all, patients with 1p19q co-deleted tumors should be treated with RT and adjuvant PCV while those lacking this co-deletion should receive adjuvant TMZ. Leptomeningeal spread can occur rarely in late stages of the disease. Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. Nature 483, 479483. Both authors have read and approved the final manuscript. doi: 10.1371/journal.pone.0068782, Keywords: anaplastic oligodendroglioma, PCV, IDH mutation, procarbazine, lomustine, vincristine, temozolomide, Citation: Bou Zerdan M and Assi HI (2021) Oligodendroglioma: A Review of Management and Pathways. 123, 853860. ; Fiao, C.; Garca, JF. Your care team uses this information to create a treatment plan. Oncol. 13, 20662071. At a median follow up of 7.5 years, around 80% (n = 10) patients in Arm C progressed vs. approximately 40% (n = 9) in the other arms. Cell Rep. 13, 23532361. (2016). Mason WP. Oncol. It was shown by Uhm (2010) that IDH mutations lead to the acquisition of a new enzymatic function that catalyzes the formation of D-2HG from alpha-KG. This in turn provides evidence that IDH mutations could allow cells to remain in a vulnerable state, and prone to additional DNA alterations. 56(1):195-9. Cancer Res. Primary CNS tumors are graded based on the tumor location, tumor type, extent of tumor spread, genetic findings, the patients age, and tumor remaining after surgery, if surgery is possible. Treatments are decided by the patients healthcare team based on the patients age, remaining tumor after surgery, tumor type, and tumor location. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. PNETs may also have some swelling around them. Which of the following is a common genetic alteration in oligodendroglioma, Copyright PathologyOutlines.com, Inc. Click, 30150 Telegraph Road, Suite 119, Bingham Farms, Michigan 48025 (USA). Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1. TERT mutations in glioma are often found within the promoter region. The median overall survival was 13.3 years in the RT+PCV group versus 7.8 years in the RT alone group, and progression-free survival at 10 years was 51% in the RT+PCV group versus 21% in the RT alone group. Weinberg, R. A. Bookshelf doi: 10.1038/nature16490, Friedman, H., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., et al. Despite utilizing a multimodal approach in nearly all patients, refractory seizures can still be seen in patients suffering from epilepsy in 50% of the cases before the initial surgery and 1540% of cases following surgery and anticonvulsant therapy (Smits and Duffau, 2011; You et al., 2011; Calatozzolo et al., 2012). Radiation therapy. Giannini, C.; Scheithauer, BW. To get an accurate diagnosis, a piece of tumor tissue will be removed during surgery, if possible. Cancer. A., Tosoni, A., Cavallo, G., Reni, M., Franceschi, E., Bonaldi, L., et al. Epub 2010 Feb 16. J. Neuropathol. (2006). Oncol. (1991). 35(2):204-9. Neurology 68, 18311836. J Neurooncol. doi: 10.1007/bf00146875, Rasheed, A., Herndon, J. E., Stenzel, T. T., Raetz, J. G., Kendelhardt, J., Friedman, H. S., et al. They occur primarily in adults (9.4% of all primary brain and central nervous system tumors) but are also found in children (4% of all primary brain tumors). Sipayya, V.; Sharma, I.; Sharma, KC. (2002). The chromatin appearance is finely threadlike to smudgy, often associated with pointlike basophilic chromocenters, rather than nucleoli. 2012 Jan;226(1):7-16. doi: 10.1002/path.2995. 21, 251255. J. Clin. 0000005528 00000 n [QxMD MEDLINE Link]. doi: 10.1016/s1470-2045(16)30122-x, Batchelor, T. T., Gilbert, M. R., Supko, J. G., Carson, K. A., Nabors, L. B., Grossman, S. A., et al. Temporal lobe surgery for intractable epilepsy in children: an analysis of outcomes in 126 children. Elefante A, Peca C, Del Basso De Caro ML, Russo C, Formicola F, Mariniello G, et al. "MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration". 0000018446 00000 n (2013). Oligodendroglioma is a growth of cells that starts in the brain. Other treatments may be recommended if the tumor can't be removed or if it's likely to come back after surgery. Your IP address is listed in our blacklist and blocked from completing this request. doi: 10.1200/JCO.1994.12.10.2013, Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., et al. Neuropathol. Brain Pathol. This tumor exhibits oligodendroglial-type nuclei and scanty eosinophilic fibrillar cytoplasm amidst a mucinous background. "Molecular pathology of oligodendroglial tumors.". In giant cells gliomas, giant cells were GFAP negative or weakly positive. PLoS One 11:e0163067. doi: 10.1002/path.2995, You, G., Sha, Z.-Y., Yan, W., Zhang, W., Wang, Y.-Z., Li, S.-W., et al. 0000141631 00000 n 22 (5):665-674. IDH mutated enzymes can promote proliferation and colony formation through its end metabolite 2-HG (Koivunen et al., 2012; Bittinger et al., 2013). van den Bent MJ. Cancer Res. 0000230580 00000 n doi: 10.1093/neuonc/noaa168, Jiang, B., Zhao, W., Shi, M., Zhang, J., Chen, A., Ma, H., et al. Acta Neuropathol. Detection of p 16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Boston: Butterworth Heinemann; 1997. Clinical presentation of pediatric oligodendrogliomas - ScienceDirect First, like most primary brain neoplasms in adults, this neoplasm is usually in the supratentorial brain, most commonly in the frontal lobes. J. Clin. Clear cytoplasm - useful feature (if present). Oligodendrogliomas are primary glial brain tumors that are divided into grade 2 and grade 3 tumors, with grade 3 tumors showing anaplastic features such as microvascular proliferation, necrosis,.